{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["osimertinib"],["osimertinib","gefitinib"]],"indication":"advanced EGFR-mutant NSCLC","name":"APPLE","nct_id":"NCT02856893","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=apple-nct02856893. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"APPLE","arms":[{"description":"Osimertinib until PD according to RECIST 1.1","label":"Osimertinib till progression","type":"EXPERIMENTAL"},{"description":"Gefitinib until emergence of positive T790M status (\"cfDNA T790M positive progression\") followed by Osimertinib until second PD according to RECIST 1.1","label":"Gefitinib till + blood test/progression than Osimertinib","type":"EXPERIMENTAL"},{"description":"Gefitinib until PD according to RECIST 1.1 followed by Osimertinib until PD according to RECIST 1.1","label":"Gefitinib till progression than Osimertinib","type":"ACTIVE_COMPARATOR"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2025-08-12","type":"ACTUAL"},"conditions":["NSCLC"],"enrollment":{"count":156,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Osimertinib","otherNames":["AZD9291, Tagrisso"],"type":"DRUG"},{"name":"Gefitinib","otherNames":["Iressa"],"type":"DRUG"}],"last_update":"2026-06-02","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","official_title":"APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR Mutant NSCLC Patients","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-09-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"PFS Rate at 18 Months","timeFrame":"18 months after randomization"}],"references":[{"citation":"Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Campelo RG, Madroszyk A, Mazieres J, Curcio H, Wasag B, Pretzenbacher Y, Grillet F, Dingemans AC, Dziadziuszko R. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol. 2024 Apr 20;42(12):1350-1356. doi: 10.1200/JCO.23.01521. Epub 2024 Feb 7.","pmid":"38324744","type":"DERIVED"}],"start_date":{"date":"2017-10-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)","url":"https://clinicaltrials.gov/study/NCT02856893"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/apple-nct02856893"}